Sheel Biotech
Key Fundamentals
SMECommercial ServicesServicesPrice-based figures as of · TTM
- ROCE
- 13.50%
- Debt to Equity
- 0.07
- EPS (TTM)
- —
- Book Value
- ₹62.40
- Market Cap
- —
- P/E (TTM)
- —
- P/B
- 0.91
- ROE
- 11.20%
- Dividend Yield
- 0.00%
- EBITDA
- ₹17.00 Cr
- 52W High
- ₹81.00
- 52W Low
- ₹37.80
- Volume
- 0
Peer Comparison
Services › Commercial Services › Diversified Services › Diversified Commercial Services
| ₹402.00 | 28.49 | ₹17,550 Cr | 9.92 | 0.63% | 55.80% | 69.20% | ₹1,363 Cr | ₹611 Cr | |
| ₹680.50 | 111.74 | ₹9,206 Cr | 27.76 | 0.00% | 27.90% | 12.60% | ₹2,578 Cr | ₹82 Cr | |
| ₹1,040.40 | 17.60 | ₹7,372 Cr | 2.33 | 0.68% | 14.80% | 18.50% | ₹951 Cr | ₹417 Cr | |
| ₹31.28 | 16.82 | ₹7,118 Cr | 2.05 | 0.00% | 23.10% | 16.20% | ₹1,101 Cr | ₹488 Cr | |
| ₹633.50 | 15.99 | ₹5,724 Cr | 12.18 | 4.72% | 83.80% | 30.80% | ₹674 Cr | ₹357 Cr | |
| ₹116.45 | 22.39 | ₹5,030 Cr | 3.40 | 0.00% | 9.82% | 9.21% | ₹821 Cr | ₹75 Cr | |
| Sheel Biotech (this company) | ₹56.65 | — | ₹115 Cr | 0.91 | 0.00% | 11.20% | 13.50% | — | — |
| Median 7 companies | ₹402.00 | 20.00 | ₹7,118 Cr | 3.40 | 0.00% | 23.10% | 16.20% | ₹1,026 Cr | ₹387 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 84/100
Category scores
- Quality
- 52
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 39
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 51
- Average
- Sales & profit trajectory 9% weight
- Financial Health
- 79
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 77
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 52
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
4- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 1.00 times its book value
- Company has delivered good profit growth of 20.2% CAGR over last 5 years
Weaknesses
3- The company has delivered a poor sales growth of 11.8% over past five years.
- Company has a low return on equity of 13.0% over last 3 years.
- Company has high debtors of 205 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 4 | 3 |
| Oscillators | Bullish | 2 | 4 | 3 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Bullish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 39.75
- Neutral
- MACD (12,26,9)
- −1.01
- Bearish
- SMA (50)
- 63.14
- Bearish
- SMA (200)
- 61.09
- Bearish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 5Y | +11.79% |
|---|---|
| 3Y | +7.32% |
| 1Y | +7.84% |
Net profit
| 5Y | +19.14% |
|---|---|
| 3Y | +33.89% |
| 1Y | +9.09% |
Operating cash flow
| 5Y | — |
|---|---|
| 3Y | Turned negative |
| 1Y | Turned negative |
5Y: The statements do not go back far enough for this window.
Operating margin· change in pp
| 5Y | +3.44 pp |
|---|---|
| 3Y | +4.44 pp |
| 1Y | −0.16 pp |
Trailing twelve months: The latest quarterly results are more than a year old.
Revenue by year
| Mar 2021 | ₹63.00 Cr |
|---|---|
| Mar 2022 | ₹84.00 Cr |
| Mar 2023 | ₹89.00 Cr |
| Mar 2024 | ₹103 Cr |
| Mar 2025 | ₹102 Cr |
| Mar 2026 | ₹110 Cr |
Net profit by year
| Mar 2021 | ₹5.00 Cr |
|---|---|
| Mar 2022 | ₹5.00 Cr |
| Mar 2023 | ₹5.00 Cr |
| Mar 2024 | ₹10.00 Cr |
| Mar 2025 | ₹11.00 Cr |
| Mar 2026 | ₹12.00 Cr |
Quarterly Results
₹ CrResults for the period ended Mar 2026 were due by 30 May 2026 and are not in this table yet.
| Particulars | Sep 2024 | Sep 2025 |
|---|---|---|
| Sales | 11 | 22 |
| Expenses | 14 | 20 |
| Operating Profit | −2 | 2 |
| OPM % | −22% | 8% |
| Other Income | 0 | 0 |
| Interest | 1 | 1 |
| Depreciation | 0 | 1 |
| PBT | −4 | 0 |
| Tax % | 3% | 24% |
| Net Profit | −4 | 0 |
| EPS (₹) | −2.53 | 0.13 |
Profit & Loss
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 63 | 84 | 89 | 103 | 102 | 110 |
| Expenses | 56 | 78 | 80 | 89 | 87 | 94 |
| Operating Profit | 7 | 6 | 9 | 14 | 15 | 16 |
| OPM % | 10% | 8% | 10% | 14% | 15% | 15% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 |
| Interest | 1 | 1 | 2 | 1 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 |
| PBT | 5 | 5 | 6 | 12 | 13 | 14 |
| Tax % | 0% | 2% | 20% | 15% | 16% | 16% |
| Net Profit | 5 | 5 | 5 | 10 | 11 | 12 |
| EPS (₹) | 3.31 | 3.11 | 3.5 | 7.22 | 7.2 | 5.78 |
| Div. Payout % | 0% | 28% | 25% | 12% | 14% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 15 | 20 |
| Reserves | 53 | 56 | 59 | 69 | 69 | 107 |
| Borrowings | 21 | 24 | 19 | 24 | 17 | 9 |
| Other Liabilities | 4 | 10 | 11 | 10 | 10 | 10 |
| Total Liabilities | 82 | 93 | 94 | 106 | 111 | 146 |
| Fixed Assets | 8 | 8 | 8 | 7 | 7 | 9 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 3 |
| Investments | 0 | 1 | 1 | 1 | 1 | 1 |
| Other Assets | 75 | 84 | 85 | 98 | 103 | 132 |
| Total Assets | 82 | 93 | 94 | 106 | 111 | 146 |
Cash Flow
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | — | 2 | 9 | −1 | 9 | −18 |
| Investing | — | −2 | −2 | 0 | −2 | −7 |
| Financing | — | 0 | −7 | 2 | −6 | 26 |
| Net Cash Flow | — | 0 | 0 | 0 | 0 | 2 |
| Free Cash Flow | — | 1 | 8 | −1 | 7 | −24 |
| CFO/EBITDA | — | 37 | 105 | 3 | 71 | −94 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 352 | 280 | 230 | 204 | 198 | 205 |
| Inventory Days | 55 | 120 | 177 | 263 | 272 | 212 |
| Days Payable | 30 | 85 | 75 | 37 | 29 | 22 |
| Cash Conversion Cycle | 377 | 315 | 332 | 430 | 441 | 395 |
| Working Capital Days | 348 | 274 | 255 | 256 | 275 | 361 |
| ROCE % | — | 7% | 10% | 15% | 14% | 13% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sheel Biotech insights
53 extracted metrics across FY21–FY26.
Documents
- 14 Oct 2026
- 13 Oct 2026
- 25 Sep 2026
Frequently Asked Questions about Sheel Biotech
What does Sheel Biotech Ltd do?
Where is Sheel Biotech Ltd (SHEEL) listed?
Which sector does Sheel Biotech Ltd belong to?
What is the 52-week high and low of Sheel Biotech Ltd?
What is the Return on Equity (ROE) of Sheel Biotech Ltd?
Company Information
Incorporated in November 1994, Sheel Biotech Limited specializes in biotechnology, floriculture, greenhouses, and organic projects.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SHEEL.md for Sheel Biotech Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.